Michael J. Higgins is Senior VP/COO/CFO of Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. He previously held a variety of senior business positions at Genzyme Corporation, including vice president of corporate finance. He serves on the board of directors of Microbia, Inc., Ironwood’s majority-owned subsidiary. Higgins hold a MBA from Amos Tuck School of Business Administration at Dartmouth College and a BS from Cornell University. Higgins is a second generation Irish American with roots in Counties Sligo, Clare, and Cork. He is the married father of 3 girls and lives in Lexington, MA.
Return to Life Science 50